Form 4: PMV Pharmaceuticals Director Charles Baum Reports Stock Option Grant

Director Charles M. Baum reports the acquisition of stock options in PMV Pharmaceuticals, Inc.

Summary

• Charles M. Baum, a director of PMV Pharmaceuticals, Inc., filed a Form 4 on June 10, 2024, reporting a transaction.
• On June 6, 2024, Baum acquired a stock option to purchase 67,500 shares of PMV Pharmaceuticals' common stock at an exercise price of $1.65.
• The option vests in two tranches: 22,500 shares vest on the earlier of June 6, 2025, or the day before the next annual meeting, and the remaining 45,000 shares vest in 36 equal monthly installments starting July 6, 2024.
• Baum also granted power of attorney to David H. Mack, Robert Ticktin, and Michael Carulli to handle SEC filings related to PMV Pharmaceuticals.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard reporting of stock option grants, which is a common practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Vesting schedules, like the one described, are typical and designed to incentivize long-term performance and retention.
• Comparable companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The vesting schedule may encourage the director's long-term commitment to the company.

Key Dates